skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emergence of new oral antithrombotics: a critical appraisal of their clinical potential

Review

(3029) Views  (783) Full article downloads

Authors: Michael Rud Lassen, Volker Laux

Published Date December 2008 Volume 2008:4(6) Pages 1373 - 1386
DOI: http://dx.doi.org/10.2147/VHRM.S3266

Michael Rud Lassen1, Volker Laux2

1Department of Orthopaedics and Clinical Trial Unit, Nordsjællands Hospital Hørsholm, University of Copenhagen, Hørsholm, Denmark; 2Thrombosis Research, Bayer Schering Pharma, Wuppertal, Germany

Abstract: In Western countries, venous thromboembolism (VTE) is a widespread and serious disorder, with hospital admission rates that appear to be increasing. Current anticoagulant therapies available for the prevention and treatment of VTE have several drawbacks that make them either difficult to manage effectively, due to a need for careful monitoring to control coagulation, or, in the case of parenterally administered agents, inconvenient for long-term use. To address some of these issues, new anticoagulants are in clinical development that can be orally administered and directly target specific factors in the coagulation cascade. This article reviews the rationale behind development of these novel agents and provides a critical appraisal of their clinical potential. In addition, the impact that the introduction of such agents into clinical practice would have is discussed from the patient perspective.

Keywords: antithrombotic agents, venous thromboembolism, Factor Xa, thrombin








Readers of this article also read:

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
New anticoagulants for the prevention of venous thromboembolism
Impact of genetic polymorphisms on clinical response to antithrombotics
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Deep vein thrombosis: a clinical review
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University